Current market catalysts

Rogers et OEG Sports & Entertainment prolongent leur partenariat stratégique de 10 ans

Rogers and OEG Sports & Entertainment announced a 10-year partnership extension through 2036, making Rogers Place the home of the Edmonton Oilers. As part of the celebration of Rogers Place's 10th anniversary, Rogers will distribute over 1,500 tickets to customers during the season, including 300 for the home opener on September 29 against Vancouver Canucks. The partnership includes media rights through Sportsnet and various fan engagement initiatives.

ExxonMobil Has Raised Its Dividend 43 Years Running. Here's the One Year the Streak Almost Broke.

ExxonMobil has maintained a 43-year dividend increase streak, but nearly broke it in 2020 during the COVID-19 pandemic when oil prices turned negative. Unlike competitors BP and Shell that cut dividends, ExxonMobil's CEO pledged to keep the dividend 'sacrosanct,' successfully preserving the streak through modest, steady annual increases.

Virtu Financial (VIRT) Boasts Earnings & Price Momentum: Should You Buy?

Virtu Financial (VIRT), a market-leading financial services firm, has been added to the Zacks Focus List and holds a #1 (Strong Buy) rating. Since its addition on July 31, 2023 at $18.90, shares have surged 240.9% to $64.43. Four analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $7.02 for fiscal 2026. The company boasts a 24% average earnings surprise and forecasted earnings growth of 22.5% for the current fiscal year.

Brokers Suggest Investing in Marathon Digital (MARA): Read This Before Placing a Bet

While Wall Street brokers give Marathon Digital Holdings an average recommendation of 1.91 (between Strong Buy and Buy), with 57% of 14 firms rating it as Strong Buy, the article cautions that brokerage recommendations often have a positive bias due to vested interests. The Zacks Rank system rates MARA as #3 (Hold), citing unchanged earnings estimates of -$4.39 for the current year, suggesting the stock may perform in line with the broader market rather than outperform.

Rogers and OEG Sports & Entertainment Extend Strategic Partnership for 10 More Years

Rogers and OEG Sports & Entertainment announced a 10-year extension of their strategic partnership, securing Rogers Place as the home of the Edmonton Oilers through 2036. To celebrate the arena's 10-year anniversary, Rogers is giving away over 1,500 tickets to customers throughout the season, including 300 for the Home Opener on September 29. The extension builds on an unprecedented sponsorship deal signed in 2013 and includes extensive brand placements and advertising across the arena.

Wall Street Analysts Think CleanSpark (CLSK) Is a Good Investment: Is It?

While Wall Street analysts give CleanSpark (CLSK) a strong buy recommendation with an average brokerage rating of 1.27, the article cautions that analyst recommendations often suffer from positive bias due to vested interests. The Zacks Rank system, which relies on earnings estimate revisions rather than analyst opinions, rates CLSK as a Hold (#3), suggesting investors should be cautious despite the bullish analyst consensus. The company's consensus earnings estimate has remained unchanged at -$3.97, indicating steady but negative earnings prospects.

Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients

Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoints for multiple myeloma patients.

RBC Capital Downgrades AGF Management to Sector Perform, Maintains Price Target to C$23

Tesla, XPENG Push Humanoid Robots Toward Mass Production

Tesla and XPENG are shifting the humanoid robot race from prototypes to mass production. Here's why the latest milestones matter.

William Blair Upgrades FactSet Research Systems to Outperform

Blue Owl Technology's $800M Financing Run Puts Dividend Coverage In Focus

The Print Blue Owl Technology Finance Corp. (NYSE:OTF) closed a $150 million private placement of 7.60% senior unsecured notes due September 3, 2032, on September 4. The deal was the company’s third financing since

8-K/A filing — RIVERVIEW BANCORP INC (RVSB)

Filed: 2026-09-08 AccNo: 0000939057-26-000233 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

UBS Maintains Buy on Peloton Interactive, Lowers Price Target to $10

SpaceX Bull Case 'Rests Almost Entirely' on Starship Reuse. Analyst Says Buy Anyway

Pivotal Research rates SpaceX a Buy with a $220 target, hinging on Starship's reusability.

If You Invested $100 In CrowdStrike Holdings Stock 5 Years Ago, You Would Have This Much Today

CrowdStrike Holdings (NASDAQ:CRWD) has outperformed the market over the past 5 years by 15.38% on an annualized basis producing an average annual return of 26.8%. Currently, CrowdStrike Holdings has a market

RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

UBS Maintains Buy on Marathon Petroleum, Raises Price Target to $450

How To Trade SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, And TSLA

Good Morning Traders! Today’s economic calendar kicks off the shortened trading week with limited scheduled data. The primary economic release comes at 11:00AM ET with the New York Fed’s 1-Year Inflation

Jeff Bezos, Cathie Wood Argue That AI Will Create a Labor Shortage, Not Job Losses

Jeff Bezos and Cathie Wood say AI could create a labor shortage instead of mass job losses. Here's why they share that view.

RBC Capital Reiterates Outperform on HCA Healthcare, Maintains $435 Price Target

UBS Maintains Buy on Phillips 66, Raises Price Target to $300

'Canada In Talks to Sell Nuclear-Power Technology, LNG to Poland' - Bloomberg

Verisk Analytics shares are trading lower after Barclays lowered its price target on the stock from $275 to $225.

Dyne Therapeutics shares are trading lower. The company announced it will present additional one-year Phase 1/2 ACHIEVE trial data for zeleciment basivarsen in DM1 at the 31st WMS Congress and the 2026 AANEM Annual Meeting.

UBS Maintains Buy on HF Sinclair, Raises Price Target to $126

RBC Capital Reiterates Outperform on Colgate-Palmolive, Maintains $104 Price Target

UBS Maintains Buy on Valero Energy, Raises Price Target to $450

Beam Therapeutics shares are trading lower. The company announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency.

Royalty Pharma shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint. The company had signed a $500 million funding agreement with Novartis partner Ionis that would have contributed pelacarsen royalties.

X-Energy shares are trading higher. Guggenheim reiterated the stock with a Buy rating and maintained a $57 price target.